With Seadrill and Transocean reporting earnings, some analysts out there are saying sell for some pretty ridiculous reasons. Here's why you shouldn't listen to them.

In this healthcare edition of Industry Focus, healthcare analyst Michael Douglass and healthcare contributor Todd Campbell speculate which of these two biotech titans is a better buy.

Join Motley Fool Analysts Sean O'Reilly and Vincent Shen for an investing happy hour as they discuss the alcohol industry.

Falling oil prices and rising interest rates are two catalysts that could significantly impact the banking industry over the next year in far-reaching ways.

Fool Tech analyst Nathan Hamilton recently returned from a trip to Asia and discusses some trends that Apple followers should pay attention to.

SolarCity missed their EPS guidance and suffered a double-digit drop overnight. Meanwhile, analysts are jumping to conclusions about ExxonMobil’s glaring absence from Berkshire Hathaway’s holdings disclosure, but Taylor Muckerman has his own theory. 

In this episode of Industry Focus, analysts Michael Douglass and Todd Campbell discuss the oncoming opportunity with biosimilars and identify the stocks they’re most excited about in this space.

Motley Fool Analysts Simon Erickson and Sean O’Reilly discuss two top plays for the emerging trend that is the Internet of Things

Talking about the energy stocks we secretly admire as Valentines day approach

In this week’s healthcare-focused episode of Industry Focus, analysts Michael Douglass and Todd Campbell discuss two small biotechs that recently reported hepatitis C data and look at their opportunity in this large and competitive market.